<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760980</url>
  </required_header>
  <id_info>
    <org_study_id>PXL209003</org_study_id>
    <nct_id>NCT01760980</nct_id>
  </id_info>
  <brief_title>Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the bioequivalence of the test product, Exemestane&#xD;
      25 mg tablets of Actavis Group PTC ehf. Iceland, and the reference product, Aromasin®&#xD;
      (exemestane) 25 mg tablets of Pharmacia &amp; Upjohn Company, Division of Pfizer Inc., New York,&#xD;
      United States of America in healthy male and postmenopausal female subjects, under fasting&#xD;
      conditions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Development halted by management&#xD;
  </why_stopped>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt, AUCinf and Cmax of Exemestane 25 mg tablets</measure>
    <time_frame>0, 0.333, 0.500, 0.750, 1.000, 1.250, 1.500, 1.750, 2.000, 2.500, 3.000, 3.500, 4.000, 6.000, 8.000, 12.000, 24.000, 36.000, 48.000, 72.000 and 96.000 hours post does</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test product (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B: Subjects receive Exemestane 25 mg tablets under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A: Subjects receive Aromasin 25 mg tablets on two occasions under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference product (A) Aromasin (Exemestane)</intervention_name>
    <description>Aromasin tablets will be administered under fasting conditions on two occasions</description>
    <arm_group_label>Reference product (A)</arm_group_label>
    <other_name>Aromasin (Exemestane) 25 mg tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test product (B) Exemestane</intervention_name>
    <description>Exemestane tablets will be administered under fasting conditions on one occasion</description>
    <arm_group_label>Test product (B)</arm_group_label>
    <other_name>Exemestane 25 mg tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects, 18 to 55 years of age and postmenopausal female subjects, 18&#xD;
             years to not older than 75 years of age (inclusive at time of screening).&#xD;
&#xD;
          2. Body Mass Index (BMI) between 19 and 33 kg/m2 (relates to a body mass within 15% of&#xD;
             ideal body mass for height and age).&#xD;
&#xD;
          3. Body mass not less than 50 kg.&#xD;
&#xD;
          4. Medical history, vital signs, physical examination, standard 12-lead electrocardiogram&#xD;
             (ECG) and laboratory investigations must be clinically acceptable or within laboratory&#xD;
             reference ranges for the relevant laboratory tests, unless the investigator considers&#xD;
             the deviation to be irrelevant for the purpose of the study.&#xD;
&#xD;
          5. Non-smoker or mild to moderate smoker (≤ 10 cigarettes daily).&#xD;
&#xD;
          6. Females, if:&#xD;
&#xD;
               -  Serum follicle-stimulating hormone (FSH) ≥ 25.8 mIU/mL AND a serum estradiol&#xD;
                  level of ≤ 54.7 pg/mL at screening.&#xD;
&#xD;
               -  Not of childbearing potential, e.g., has been surgically sterilized, undergone a&#xD;
                  hysterectomy, amenorrhea for ≥ 12 months and considered post-menopausal.&#xD;
&#xD;
             Note: In postmenopausal women, the value of the serum pregnancy test may be slightly&#xD;
             increased, but if not increasing upon repeat, the female will be included in the&#xD;
             study.&#xD;
&#xD;
             • Not on thyroid hormone replacement therapy or on stable thyroid hormone replacement&#xD;
             therapy for at least 3 months before the first administration of IMP.&#xD;
&#xD;
             Not on statin therapy or on stable statin therapy for at least 3 months before the&#xD;
             first administration of IMP.&#xD;
&#xD;
             • Blood pressure measurements are within the acceptable ranges; or, if diagnosed with&#xD;
             hypertension, are on stable therapy for at least 3 months before the first&#xD;
             administration of IMP.&#xD;
&#xD;
             Note: Treatment with calcium channel blockers is NOT allowed.&#xD;
&#xD;
          7. Written consent given for participation in the study. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional&#xD;
             or intellectual problems likely to limit the validity of consent to participate in the&#xD;
             study or limit the ability to comply with protocol requirements.&#xD;
&#xD;
          2. Current alcohol use &gt; 21 units of alcohol per week for males and &gt; 14 units of alcohol&#xD;
             per week for females.&#xD;
&#xD;
          3. History of regular exposure to substances of abuse (other than alcohol) within the&#xD;
             past year.&#xD;
&#xD;
          4. Use of any medication, prescribed or over-the-counter or herbal remedies, within 2&#xD;
             weeks prior to the first administration of IMP, except for medication allowed per&#xD;
             inclusion criteria (Section 7.3.1) or if the medication will not affect the outcome of&#xD;
             the study in the opinion of the investigator.&#xD;
&#xD;
          5. Female hormone replacement therapy (or other medicine containing estrogen, including&#xD;
             health food products for menopausal symptoms, as these may contain natural estrogens),&#xD;
             within 2 weeks prior to the first administration of IMP.&#xD;
&#xD;
          6. Participation in another study with an experimental drug, where the last&#xD;
             administration of the previous IMP was within 8 weeks before the first administration&#xD;
             of IMP in this study.&#xD;
&#xD;
          7. Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the&#xD;
             first administration of IMP.&#xD;
&#xD;
          8. Treatment within the previous 3 months before the first administration of IMP with any&#xD;
             drug with a well-defined potential for adversely affecting a major organ or system.&#xD;
&#xD;
          9. A major illness during the 3 months before commencement of the screening period.&#xD;
&#xD;
         10. History of hypersensitivity or allergy to the IMP or its excipients or any related&#xD;
             medication.&#xD;
&#xD;
         11. History of bronchial asthma or any other bronchospastic disease within the past 5&#xD;
             years.&#xD;
&#xD;
         12. History of epilepsy.&#xD;
&#xD;
         13. History of porphyria.&#xD;
&#xD;
         14. Relevant history or laboratory or clinical findings indicative of acute or chronic&#xD;
             disease, likely to influence study outcome.&#xD;
&#xD;
         15. Systolic blood pressure &gt; 150 mmHg or &lt; 95 mmHg, and/or diastolic blood pressure &gt; 95&#xD;
             mmHg or &lt; 50 mmHg in either the supine or standing position at screening.&#xD;
&#xD;
         16. Resting pulse of &gt; 100 beats per minute or &lt; 45 beats per minute in either the supine&#xD;
             or standing position at screening.&#xD;
&#xD;
         17. Positive serology testing for human immunodeficiency virus (HIV), Hepatitis B,&#xD;
             Hepatitis C or syphilis.&#xD;
&#xD;
         18. Positive urine screen for drugs of abuse.&#xD;
&#xD;
         19. Positive pregnancy test.&#xD;
&#xD;
         20. Female subjects of premenopausal endocrine status, including pregnant and lactating&#xD;
             women.&#xD;
&#xD;
         21. Clinically diagnosed peptic ulceration within the past 5 years.&#xD;
&#xD;
         22. History of bleeding disorders.&#xD;
&#xD;
         23. Vegetarian or any abnormal diet (for whatever reason).&#xD;
&#xD;
         24. Any specific investigational product safety concern. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa)</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rate and extend of absorption of Exemestane</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

